首页> JTO clinical and research reports> Docetaxel Plus Ramucirumab With Primary Prophylactic Pegylated Granulocyte-Colony Stimulating Factor Support for Elderly Patients With Advanced NSCLC: A Multicenter Prospective Single Arm Phase 2 Trial: DRAGON Study (WJOG9416L).

Docetaxel Plus Ramucirumab With Primary Prophylactic Pegylated Granulocyte-Colony Stimulating Factor Support for Elderly Patients With Advanced NSCLC: A Multicenter Prospective Single Arm Phase 2 Trial: DRAGON Study (WJOG9416L).

导出 LinkOut

翻译打印收藏纠错

第一作者： Motoko,Tachihara

第一单位： Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.

作者： Motoko,Tachihara ^[1] ; Akito,Hata ^[2] ; Takaaki,Tokito ^[3] ; Satoshi,Hara ^[4] ; Hideaki,Okada ^[2] ; Satoru,Miura ^[5] ; Yuki,Sato ^[6] ; Eriko,Tabata ^[7] ; Hiroshi,Watanabe ^[8] ; Yusuke,Takayama ^[9] ; Ryo,Toyozawa ^[10] ; Keiichi,Ota ^[11] ; Kazushige,Wakuda ^[12] ; Atsushi,Nakamura ^[13] ; Mototsugu,Shimokawa ^[14] ; Nobuyuki,Yamamoto ^[15] ; Kazuhiko,Nakagawa ^[16]

作者单位： Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan. ^[1] Division of Thoracic Oncology, Kobe Minimally Invasive Cancer Center, Kobe, Japan. ^[2] Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University, Kurume, Japan. ^[3] Department of Respiratory Medicine, Itami City Hospital, Itami, Japan. ^[4] Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan. ^[5] Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan. ^[6] Department of Respiratory Medicine, Ikeda City Hospital, Ikeda, Japan. ^[7] Department of Respiratory Medicine, Saka General Hospital, Shiogama, Japan. ^[8] Department of Respiratory Medicine, Hiroshima Citizens Hospital, Hiroshima, Japan. ^[9] Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan. ^[10] Research Institute for Diseases of the Chest, Kyushu University Hospital, Fukuoka, Japan. ^[11] Division of Thoracic Oncology, Shizuoka Cancer Center, Mishima, Japan. ^[12] Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan. ^[13] Department of Biostatistics, Yamaguchi University Graduate School of Medicine Yamaguchi, Ube, Japan. ^[14] Internal Medicine III, Wakayama Medical University, Wakayama, Japan. ^[15] Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan. ^[16]

关键词 Docetaxel Febrile neutropenia Non–small cell lung cancer Ramucirumab elderly pegylated-granulocyte-colony stimulating factor

DOI 10.1016/j.jtocrr.2023.100569

PMID 37822699

发布时间 2023-10-18

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

JTO clinical and research reports

2023年4卷10期

100569页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

JTO clinical and research reports

2023年4卷10期

100569页

检索历史清除

Docetaxel Plus Ramucirumab With Primary Prophylactic Pegylated Granulocyte-Colony Stimulating Factor Support for Elderly Patients With Advanced NSCLC: A Multicenter Prospective Single Arm Phase 2 Trial: DRAGON Study (WJOG9416L).

JTO clinical and research reports

相似文献

JTO clinical and research reports

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Docetaxel Plus Ramucirumab With Primary Prophylactic Pegylated Granulocyte-Colony Stimulating Factor Support for Elderly Patients With Advanced NSCLC: A Multicenter Prospective Single Arm Phase 2 Trial: DRAGON Study (WJOG9416L).

JTO clinical and research reports

相似文献

JTO clinical and research reports

相关期刊

检索历史清除